Zim LaboratoriesNSE:ZIMLAB -2.32%76 Interest Coverage is 0.63 as of Mar. 2026, which is 78% below its 10-year median of 2.93. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 685 Drug Manufacturers companies, Zim Laboratories ranks worse than 95.33% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zim Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₹21 Mil. Zim Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₹-33 Mil.
Zim Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 0.63.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Zim Laboratories's Interest Coverage or its related term are showing as below:
NSE:ZIMLAB'
s Interest Coverage Range Over the Past 10 Years
Min: 0.76 Med: 2.93 Max: 7.09
Current: 0.76
NSE:ZIMLAB's Interest Coverage is ranked worse than 95.33% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs NSE:ZIMLAB: 0.76
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zim Laboratories Interest Coverage Related Terms
Zim Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a Interest Coverage of 0.63 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zim Laboratories and its competitors. This is 78% below median its historical median of 2.93. Over the past decade, Zim Laboratories' Interest Coverage has ranged from 0.76 to 7.09. According to the industry distribution chart, Zim Laboratories ranks #653 out of 685 companies in the Drug Manufacturers industry, placing it in the top 95.3%.
Is Zim Laboratories' Interest Coverage too high?
Zim Laboratories' current Interest Coverage of 0.63 is 78% below median its 10-year median of 2.93. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 7.09. The Drug Manufacturers industry median Interest Coverage is 12.78. Zim Laboratories' value of 0.63 is 95.1% below this industry median. Based on the distribution chart, Zim Laboratories ranks #653 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #653 out of 685 companies for Interest Coverage. This places Zim Laboratories in the lower half of its industry. The industry median Interest Coverage is 12.78. Zim Laboratories' value of 0.63 is 95.1% below this benchmark. Historically, Zim Laboratories' own Interest Coverage has ranged from 0.76 to 7.09 over the past decade. While the company's 10-year median is 2.93 vs. the industry median of 12.78, Zim Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current Interest Coverage of 0.63 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current Interest Coverage is 0.63, which is 78% below median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current Interest Coverage is 0.63, which is 78% below median its 10-year median of 2.93 and 95.1% below the Drug Manufacturers industry median of 12.78. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Interest Coverage is 0.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
Interest Coverage: 0.63 (78% below median its 10-year median of 2.93)
GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
Industry Position: 95.1% below the Drug Manufacturers median (#653 of 685)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score
Get the complete analysis for NSE:ZIMLAB
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
